OBJECTIVE: To compare vision-related functioning and health-related quality of life of patients with noninfectious intermediate or posterior uveitis with those of the US general population and normal-vision reference groups. METHODS: Secondary analysis of health-related quality of life measures administered at baseline to patients with noninfectious intermediate or posterior uveitis participating in the HURON trial, a 26-week, multicenter, masked, randomized, sham-controlled trial of a dexamethasone intravitreal implant (n=224) was performed. Patient-reported outcome measures included the National Eye Institute Visual Function Questionnaire-25, the 36-Item Short-Form Health Survey, the Short Form-6 Dimensions, and the EuroQol-5D. The National Eye Institute Visual Function Questionnaire-25 scores from the HURON uveitis population were compared with published National Eye Institute Visual Function Questionnaire-25 scores from a normal-vision reference group (n=122). The 36-Item Short-Form Health Survey, Short Form-6 Dimensions, and EuroQol-5D scores were compared with the US general population using data from the National Health Measurement Study (n=3844) and the Medical Expenditure Panel Survey (n=955). RESULTS: Compared with a normal-vision population, the HURON uveitis population had clinically significant impairments across all National Eye Institute Visual Function Questionnaire-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P< .001). The HURON uveitis population had significantly lower 36-Item Short-Form Health Survey mental component summary and Short Form-6 Dimensions scores compared with a US general population sample (P< .001). No significant differences were found for the 36-Item Short-Form Health Survey physical component summary and EuroQol-5D scores between the uveitis and US general population samples. CONCLUSIONS: Compared with the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, health-related quality of life, and vision-related functioning. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT00333814.
RCT Entities:
OBJECTIVE: To compare vision-related functioning and health-related quality of life of patients with noninfectious intermediate or posterior uveitis with those of the US general population and normal-vision reference groups. METHODS: Secondary analysis of health-related quality of life measures administered at baseline to patients with noninfectious intermediate or posterior uveitis participating in the HURON trial, a 26-week, multicenter, masked, randomized, sham-controlled trial of a dexamethasone intravitreal implant (n=224) was performed. Patient-reported outcome measures included the National Eye Institute Visual Function Questionnaire-25, the 36-Item Short-Form Health Survey, the Short Form-6 Dimensions, and the EuroQol-5D. The National Eye Institute Visual Function Questionnaire-25 scores from the HURON uveitis population were compared with published National Eye Institute Visual Function Questionnaire-25 scores from a normal-vision reference group (n=122). The 36-Item Short-Form Health Survey, Short Form-6 Dimensions, and EuroQol-5D scores were compared with the US general population using data from the National Health Measurement Study (n=3844) and the Medical Expenditure Panel Survey (n=955). RESULTS: Compared with a normal-vision population, the HURON uveitis population had clinically significant impairments across all National Eye Institute Visual Function Questionnaire-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P< .001). The HURON uveitis population had significantly lower 36-Item Short-Form Health Survey mental component summary and Short Form-6 Dimensions scores compared with a US general population sample (P< .001). No significant differences were found for the 36-Item Short-Form Health Survey physical component summary and EuroQol-5D scores between the uveitis and US general population samples. CONCLUSIONS: Compared with the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, health-related quality of life, and vision-related functioning. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT00333814.
Authors: Katherine M Niemeyer; John A Gonzales; Thuy Doan; Erica N Browne; Maya M Rao; Nisha R Acharya Journal: Am J Ophthalmol Date: 2019-06-13 Impact factor: 5.258
Authors: Katherine M Niemeyer; John A Gonzales; Sivakumar R Rathinam; Manohar Babu; Radhika Thundikandy; Anuradha Kanakath; Travis C Porco; Erica N Browne; Maya M Rao; Nisha R Acharya Journal: Am J Ophthalmol Date: 2017-04-14 Impact factor: 5.258
Authors: Anne M Rentz; Jonathan W Kowalski; John G Walt; Ron D Hays; John E Brazier; Ren Yu; Paul Lee; Neil Bressler; Dennis A Revicki Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Christopher J Brady; Andrea C Villanti; Hua Andrew Law; Ehsan Rahimy; Rahul Reddy; Pamela C Sieving; Sunir J Garg; Johnny Tang Journal: Cochrane Database Syst Rev Date: 2016-02-12
Authors: Joseph McDonald; Amy Cassedy; Mekibib Altaye; Jennifer Andringa; Ashley M Cooper; Carolyn Drews-Botsch; George Engelhard; Theresa Hennard; Gary N Holland; Kirsten Jenkins; Scott R Lambert; Jessi Lipscomb; Courtney McCracken; Deborah K McCurdy; Najima Mwase; Sampath Prahalad; Jessica Shantha; Erin Stahl; Virginia Miraldi Utz; A Adrienne Walker; Steven Yeh; Sheila T Angeles-Han Journal: Arthritis Care Res (Hoboken) Date: 2022-06-08 Impact factor: 5.178
Authors: Alastair K Denniston; Gary N Holland; Andrej Kidess; Robert B Nussenblatt; Annabelle A Okada; James T Rosenbaum; Andrew D Dick Journal: Orphanet J Rare Dis Date: 2015-08-19 Impact factor: 4.123